© 2002 by the American Diabetes Association, Inc.
Ghrelin Is Present in Pancreatic
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ABSTRACT |
|---|
|
|
|---|
-cells. We identified ghrelin and des-acyl ghrelin in the rat pancreas using reverse-phase high-performance liquid chromatography combined with two radioimmunoassays. We also detected mRNA encoding ghrelin and its receptor in the rat pancreatic islets. Ghrelin increased the cytosolic free Ca2+ concentration in ß-cells and stimulated insulin secretion when it was added to isolated rat pancreatic islets. These findings indicate that ghrelin may regulate islet function in an endocrine and/or paracrine manner.
| INTRODUCTION |
|---|
|
|
|---|
In the present study, we investigated the cellular source of ghrelin in rat and human pancreas by immunohistochemistry. Ghrelin molecules in rat pancreas were characterized by reverse-phase high-performance liquid chromatography (RP-HPLC) combined with radioimmunoassay (RIA). The expression of ghrelin and its receptor was examined by reverse transcriptionpolymerase chain reaction (RT-PCR). Finally, we studied the effects of ghrelin on the insulin secretion from rat pancreatic islets and the cytosolic free Ca2+ concentration ([Ca2+]i) in rat pancreatic ß-cells, a widely known mediator of a variety of ß-cell functions (13,14,15).
| RESEARCH DESIGN AND METHODS |
|---|
|
|
|---|
RIAs for ghrelin.
Two ghrelin-specific RIAs were developed as previously described (16). Two kinds of polyclonal antibodies were raised against the COOH-terminally Cys-extended rat ghrelin (position 111) with octanoylated Ser-3 and NH2-terminally Cys-extended rat ghrelin (position 1328) in New Zealand white rabbits. An antirat ghrelin (111) antiserum (#G606) specifically recognized ghrelin with n-octanoylated Ser 3 and did not recognize des-acyl ghrelin. An antirat ghrelin (1328) antiserum (#G107) recognized n-octanoyl modified and des-acyl ghrelin equally. Both antisera had 100% cross-reactivity with human ghrelin (128).
Synthetic rat [Tyr29]-ghrelin (128) and [Tyr0]-ghrelin (1328) were radioiodinated by the lactoperoxidase method (16). Diluted samples or standard peptide solutions (100 µl) were incubated for 24 h with 100 µl of the antiserum diluent (final dilution of antighrelin (111) antiserum, 1:620,000; final dilution of antighrelin (1328) antiserum, 1:20,000). A tracer solution (16,000 cpm in 100 µl) was added, and the mixture was incubated for another 24 h. The bound and free ligands were separated using a second antibody (200 µl). All of the procedures were performed at 4°C, and the samples were assayed in duplicate. Half-maximal inhibition by rat ghrelin (128) on the standard RIA curve with antighrelin (111) antiserum was 3.8 fmol/tube and with anti-ghrelin (1328) antiserum was 80 fmol. The intra- and interassay coefficients of variation for NH2-terminus RIA were 3.5 and 3.2%, respectively, and those for COOH-terminus RIA were 3.7 and 3.3%, respectively.
Quantification and chromatographic characterization of immunoreactive ghrelin in rat pancreas.
Peptide extracts from three rat pancreata were loaded onto Sep-Pak C-18 cartridge (Waters, Milword, MA), and the bound peptides were eluted with 60% acetonitrile (CH3CN) solution containing 0.1% trifluoroacetic acid (TFA). A fraction of the eluate was subjected to two RIAs for ghrelin, and the remainder was used for RP-HPLC under the conditions described in Fig. 1. All of the HPLC fractions were quantified by the ghrelin RIA. n-Octanoylated rat ghrelin (128) and des-acyl rat ghrelin (128) were chromatographed using the same HPLC system as standards.
|
Human pancreata obtained at autopsy from three patients who had died of cardiovascular disease were immersed in the same fixative for 24 h at 4°C. They were cut at -20°C with a cryostat into 12-µm-thick slices, then incubated overnight at 4°C with antighrelin (111) antiserum (final dilution, 1:5,000), antighrelin (1328) antiserum (final dilution, 1:5,000), or anti-glucagon antiserum (dilution, 1:500). The slides were stained by the avidin-biotin-peroxidase complex method (Vectastain Elite ABC kit; Vector Laboratories, Burlingame, CA) as described previously (11).
Immunohistochemical double-staining.
The rat pancreatic sections were incubated overnight at 4°C with sheep anti-glucagon antiserum (Biogenesis, England, U.K.; dilution, 1:1,000) and then with Alexa Fluor 594 donkey anti-sheep IgG (Molecular Probes). Next, the sections were incubated with antighrelin (1328) antiserum (final dilution, 1:3,000) and then with Alexa Fluor 488 goat anti-rabbit IgG (Molecular Probes). The slides were observed by fluorescence microscopy (BH2-RFC; Olympus).
RT-PCR for ghrelin and ghrelin receptor.
Total RNA was individually extracted from the pancreata and the isolated islets of Langerhans of Wistar rats by the acid guanidinium thiocyanate-phenol-chloroform method (17). First-strand cDNA was synthesized from 2.5 µg of RNA and oligo (dT)18 primer using ReverTra Ace-
(Toyobo, Osaka, Japan) and then subjected to PCR amplification using primers specific for ghrelin or the ghrelin receptor as described elsewhere (11). The PCR products were electrophoresed on a 2% agarose gel (FMC BioProducts, Rockland, ME). Some portions of the PCR products of ghrelin and the ghrelin receptor were digested with PstI and HinfI, respectively, then electrophoresed. The other portions of the PCR products were purified with Magic PCR DNA Purification System (Promega, Madison, WI) and then sequenced by BigDye Terminator Cycle Sequencing System (Applied Biosystems, Foster City, CA).
Preparation of islets and single ß-cells.
Wistar rats aged 1012 weeks were anesthetized with an intraperitoneal injection of sodium pentobarbital (80 mg/kg body wt). After the abdomen was opened, the common bile duct proximal to the pancreas was first ligated, and then collagenase (3 mg/ml) dissolved in 5 mmol/l Ca2+-containing Krebs-Ringer bicarbonate buffer (KRB) was injected into the common bile duct at the distal end. The pancreas was resected and incubated at 37°C for 17 min. Islets were hand-collected under a microscope and either used for the study of insulin release or dispersed into single cells by treatment with Ca2+-free KRB + 0.1 mmol/l EGTA. The single cells were plated on coverslips and maintained in a short-term culture for up to 2 days in Eagles minimum essential medium containing 5.6 mmol/l glucose supplemented with 10% fetal bovine serum, 100 mg/ml streptomycin, and 100 mU/ml penicillin at 37°C in a 95% air and 5% CO2 atmosphere. The cells during this culture period responded to test agents in a consistent manner. ß-Cells were selected by immunostaining with anti-insulin antiserum or by morphological and physiological criteria, as reported previously (18,19).
Measurement of insulin release from islets.
Insulin release from rat pancreatic islets was examined as described previously (19,20). Briefly, groups of seven isolated islets were first incubated for 30 min in KRB containing 2.8 mmol/l glucose for stabilization. The islets then were incubated at 37°C for 30 min in KRB containing 2.8 or 8.3 mmol/l glucose, either with or without the addition of 10-12 mol/l ghrelin. At the end of the incubation period, aliquots of the medium were collected for the measurement of insulin concentration with an enzyme immunoassay kit (Morinaga, Yokohama, Japan).
Measurement of [Ca2+]i in single ß-cells.
[Ca2+]i was measured by dual-wavelength fura-2 microfluorometry combined with digital imaging as reported previously (20). Briefly, cells on coverslips were incubated with 2 mmol/l fura-2 acetoxymethyl ester in KRB containing 2.8 mmol/l glucose for 30 min at 37°C. They were then mounted in a chamber and superfused with KRB at a rate of 1 ml/min at 37°C. The cells were excited alternately at 340 and 380 nm every 2.5 s, emission signals at 510 nm were detected with an intensified charge-coupled device camera, and ratio images were produced by an Argus-50 system (Hamamatsu Photonics, Hamamatsu, Japan). Ratio values were converted to [Ca2+]i according to calibration curves (20).
Statistical analysis.
All the data are presented as means ± SE, and comparisons between groups were performed by unpaired t test. The level of significance was set at P < 0.05.
| RESULTS |
|---|
|
|
|---|
Immunohistochemistry.
Ghrelin-immunoreactive cells were found in the mantle of the pancreatic islets, just like glucagon-producing
-cells (Figs. 2AC and EH). In rat islets, ghrelin-immunoreactive cells co-localized with glucagon in immunofluorescence double-staining (Fig. 2D). In humans, ghrelin-immunoreactive cells also had the same distribution as
-cells (Figs. 2EH).
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
20% of all endocrine cells in the oxyntic mucosae of both rats and humans, represent a major endocrine cell population in the oxyntic gland (22,23), their hormonal product and physiological functions have not previously been clarified. The present study shows that ghrelin is present in the
-cells of rat and human pancreas. X cells also have been called A(
)-like cells; although they do not exhibit glucagon-immunoreactivity, they do share some morphological features with pancreatic
-cells, including the presence of compact and dense secretory granules. Although
-cells are lacking or scarce in the gastric fundus of mammals except for dogs and cats, they are fairly abundant in the fundic mucosa of human fetuses (24,25). These findings suggest that pancreatic
-cells and gastric ghrelin cells may originate from the same endodermal progenitor cells.
The pancreatic islets vary in size and cellularity but generally are composed of four main cell types:
(20% of the total), ß (68%),
(10%), and PP (2%) (26). Insulin-producing ß-cells are located in the center of the islet, and glucagon-producing
-cells are found at the periphery, with somatostatin-producing
-cells interposed between the two. One widely accepted model of the vascular supply in the islets proposes that arterial blood is first carried to the ß-cellrich center before passing on to the
- and
-cells in the periphery (27). Both ghrelin and its receptor are present in the pancreatic islets. Therefore, ghrelin in
-cells may affect islet functions via the systemic circulation. There is another possibility that ghrelin may interact with insulin, somatostatin, or both in a paracrine manner independent of blood flow, because
-, ß-, and
-cells are often in intimate contact within the islets and gap junctions exist between these cells.
Ghrelin at 10-12 mol/l stimulated insulin release and increased [Ca2+]i in rat islet ß-cells in the presence of a stimulatory (8.3 mmol/l) but not basal (2.8 mmol/l) glucose concentration. Ghrelin at a higher concentration of 10-8 mol/l showed lesser effects on both insulin release and [Ca2+]i increase, and at 10-14 mol/l it had no effects (data not shown). Ghrelin promotes calcium release after it binds to the ghrelin receptor (4). These findings suggest that ghrelin is a novel potentiator of insulin release and that Ca2+ may be a messenger signal for ghrelin in ß-cells. Considering that the plasma level of n-octanoylated ghrelin in rats is 4 x 10-12 mol/l (16), the effects of ghrelin at 10-12 mol/l on insulin release and [Ca2+]i increase are thought to be physiological. Ghrelin may serve as a physiological regulator of insulin release. Because increases and oscillations of [Ca2+]i have been implicated not only in insulin release but also in insulin synthesis and gene expression (13,14,15), ghrelin might serve as a trophic factor for islet ß-cells, although additional studies are definitely needed.
Ghrelin stimulates insulin secretion, whereas ghrelin secretion from
-cells may be regulated by the plasma concentration of glucose and/or insulin. We recently showed that ghrelin mRNA expression in the rat stomach is upregulated upon fasting and insulin-induced hypoglycemia (28). These findings suggest that ghrelin may function as an anabolic signal molecule during energy depletion. The presence of ghrelin and its receptor in the pancreatic islets provides a new clue for our understanding of the regulation of energy homeostasis.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
Received for publication 8 August 2001 and accepted in revised form 3 October 2001.
[Ca2+]i, cytosolic free Ca2+ concentration; GH, growth hormone; GHS, growth-hormone secretagogue; GHS-R, GHS receptor; ICV, intracerebroventricularly; IV, intravenously; KRB, Krebs-Ringer bicarbonate buffer; PBS, phosphate-buffered saline; RIA, radioimmunoassay; RP-HPLC, reverse-phase high-performance liquid chromatography; RT-PCR, reverse transcriptionpolymerase chain reaction; TFA, trifluoroacetic acid.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. Edfalk, P. Steneberg, and H. Edlund Gpr40 Is Expressed in Enteroendocrine Cells and Mediates Free Fatty Acid Stimulation of Incretin Secretion Diabetes, September 1, 2008; 57(9): 2280 - 2287. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. P. Esler, J. Rudolph, T. H. Claus, W. Tang, N. Barucci, S.-E. Brown, W. Bullock, M. Daly, L. DeCarr, Y. Li, et al. Small-Molecule Ghrelin Receptor Antagonists Improve Glucose Tolerance, Suppress Appetite, and Promote Weight Loss Endocrinology, November 1, 2007; 148(11): 5175 - 5185. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Takahashi, Y. Kurose, M. Sakaida, Y. Suzuki, S. Kobayashi, T. Sugino, M. Kojima, K. Kangawa, Y. Hasegawa, and Y. Terashima Ghrelin differentially modulates glucose-induced insulin secretion according to feeding status in sheep J. Endocrinol., September 1, 2007; 194(3): 621 - 625. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Dezaki, M. Kakei, and T. Yada Ghrelin Uses G{alpha}i2 and Activates Voltage-Dependent K+ Channels to Attenuate Glucose-Induced Ca2+ Signaling and Insulin Release in Islet {beta}-Cells: Novel Signal Transduction of Ghrelin Diabetes, September 1, 2007; 56(9): 2319 - 2327. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gauna, R. M. Kiewiet, J. A. M. J. L. Janssen, B. van de Zande, P. J. D. Delhanty, E. Ghigo, L. J. Hofland, A. P. N. Themmen, and A. J. van der Lely Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E697 - E704. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Piccoli, L. Degen, C. MacLean, S. Peter, L. Baselgia, F. Larsen, C. Beglinger, and J. Drewe Pharmacokinetics and Pharmacodynamic Effects of an Oral Ghrelin Agonist in Healthy Subjects J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1814 - 1820. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Gromada, I. Franklin, and C. B. Wollheim {alpha}-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains Endocr. Rev., February 1, 2007; 28(1): 84 - 116. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Granata, F. Settanni, L. Biancone, L. Trovato, R. Nano, F. Bertuzzi, S. Destefanis, M. Annunziata, M. Martinetti, F. Catapano, et al. Acylated and Unacylated Ghrelin Promote Proliferation and Inhibit Apoptosis of Pancreatic {beta}-Cells and Human Islets: Involvement of 3',5'-Cyclic Adenosine Monophosphate/Protein Kinase A, Extracellular Signal-Regulated Kinase 1/2, and Phosphatidyl Inositol 3-Kinase/Akt Signaling Endocrinology, February 1, 2007; 148(2): 512 - 529. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhu, Y. Cao, K. Voodg, and D. F. Steiner On the Processing of Proghrelin to Ghrelin J. Biol. Chem., December 15, 2006; 281(50): 38867 - 38870. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Dezaki, H. Sone, M. Koizumi, M. Nakata, M. Kakei, H. Nagai, H. Hosoda, K. Kangawa, and T. Yada Blockade of Pancreatic Islet-Derived Ghrelin Enhances Insulin Secretion to Prevent High-Fat Diet-Induced Glucose Intolerance Diabetes, December 1, 2006; 55(12): 3486 - 3493. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Naslund and J. G. Kral Impact of Gastric Bypass Surgery on Gut Hormones and Glucose Homeostasis in Type 2 Diabetes Diabetes, December 1, 2006; 55(Supplement_2): S92 - S97. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Choi, Y. M. Cho, M. K. Moon, H. H. Choi, H. D. Shin, H. C. Jang, S. Y. Kim, H. K. Lee, and K. S. Park Polymorphisms in the Ghrelin Gene Are Associated with Serum High-Density Lipoprotein Cholesterol Level and not with Type 2 Diabetes Mellitus in Koreans J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4657 - 4663. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Damjanovic, N. M. Lalic, P. M. Pesko, M. S. Petakov, A. Jotic, D. Miljic, K. S. Lalic, L. Lukic, M. Djurovic, and V. B. Djukic Acute Effects of Ghrelin on Insulin Secretion and Glucose Disposal Rate in Gastrectomized Patients J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2574 - 2581. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. ThidarMyint, H. Yoshida, T. Ito, and H. Kuwayama Dose-dependent response of plasma ghrelin and growth hormone concentrations to bovine ghrelin in Holstein heifers. J. Endocrinol., June 1, 2006; 189(3): 655 - 664. [Abstract] [Full Text] [PDF] |
||||
![]() |
H Takahashi, Y Kurose, S Kobayashi, T Sugino, M Kojima, K Kangawa, Y Hasegawa, and Y Terashima Ghrelin enhances glucose-induced insulin secretion in scheduled meal-fed sheep. J. Endocrinol., April 1, 2006; 189(1): 67 - 75. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Nakahara, M. Nakagawa, Y. Baba, M. Sato, K. Toshinai, Y. Date, M. Nakazato, M. Kojima, M. Miyazato, H. Kaiya, et al. Maternal Ghrelin Plays an Important Role in Rat Fetal Development during Pregnancy Endocrinology, March 1, 2006; 147(3): 1333 - 1342. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Stanley, K. Wynne, B. McGowan, and S. Bloom Hormonal Regulation of Food Intake Physiol Rev, October 1, 2005; 85(4): 1131 - 1158. [Abstract] [Full Text] [PDF] |
||||
![]() |
M A Arafat, B Otto, H Rochlitz, M Tschop, V Bahr, M Mohlig, S Diederich, J Spranger, and A F H Pfeiffer Glucagon inhibits ghrelin secretion in humans Eur. J. Endocrinol., September 1, 2005; 153(3): 397 - 402. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nishi, H. Hiejima, H. Hosoda, H. Kaiya, K. Mori, Y. Fukue, T. Yanase, H. Nawata, K. Kangawa, and M. Kojima Ingested Medium-Chain Fatty Acids Are Directly Utilized for the Acyl Modification of Ghrelin Endocrinology, May 1, 2005; 146(5): 2255 - 2264. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Iwakura, K. Hosoda, C. Son, J. Fujikura, T. Tomita, M. Noguchi, H. Ariyasu, K. Takaya, H. Masuzaki, Y. Ogawa, et al. Analysis of Rat Insulin II Promoter-Ghrelin Transgenic Mice and Rat Glucagon Promoter-Ghrelin Transgenic Mice J. Biol. Chem., April 15, 2005; 280(15): 15247 - 15256. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kojima and K. Kangawa Ghrelin: Structure and Function Physiol Rev, April 1, 2005; 85(2): 495 - 522. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Wei, G. Wang, X. Qi, E. W. Englander, and G. H. Greeley Jr. Characterization and Regulation of the Rat and Human Ghrelin Promoters Endocrinology, March 1, 2005; 146(3): 1611 - 1625. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Wynne, S. Stanley, B. McGowan, and S. Bloom Appetite control J. Endocrinol., February 1, 2005; 184(2): 291 - 318. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Osawa, M. Nakazato, Y. Date, H. Kita, H. Ohnishi, H. Ueno, T. Shiiya, K. Satoh, Y. Ishino, and K. Sugano Impaired Production of Gastric Ghrelin in Chronic Gastritis Associated with Helicobacter pylori J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 10 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ariyasu, K. Takaya, H. Iwakura, H. Hosoda, T. Akamizu, Y. Arai, K. Kangawa, and K. Nakao Transgenic Mice Overexpressing Des-Acyl Ghrelin Show Small Phenotype Endocrinology, January 1, 2005; 146(1): 355 - 364. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. L. Jeffery, R. P. Duncan, A. H. Yeh, R. A. Jaskolski, D. S. Hammond, A. C. Herington, and L. K. Chopin Expression of the Ghrelin Axis in the Mouse: An Exon 4-Deleted Mouse Proghrelin Variant Encodes a Novel C Terminal Peptide Endocr |